Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma

Clinical Orthopaedics and Related Research

Volumn 376, Issue , 2000, Pages 200-208

  Shin, Kyoo Ho ^a   Moon, Seong Hwan ^a   Suh, Jin Suck ^a   Yang, Woo Ick ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN;

ARTICLE; CLINICAL ARTICLE; HISTOPATHOLOGY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; REPRODUCIBILITY; THREE DIMENSIONAL IMAGING; TUMOR VOLUME;

EID: 0033922472     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/00003086-200007000-00027     Document Type: Article

References (38)

1. Bacci G, Ferrari S, Delepine N, et al: Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: Study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol 16:658-663, 1998.
2. Bieling P, Rehan N, Winkler P, et al: Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 14:848-858, 1996.
3. Bonnerot V, Charpentier A, Frouin F, et al: Factor analysis of dynamic magnetic resonance imaging in predicting the response of osteosarcoma to chemotherapy. Invest Radiol 27:847-855, 1992.
4. Bronstrom LA, Strander H, Nilsonne U: Survival on osteosarcoma in relation to tumor size and location. Clin Orthop 167:250-254, 1982.
5. Burgers JM, Van Glabbeke M, Busson A, et al: Osteosarcoma of the limb. Report of the EORTC-SIOP 03 trial 20781 investigating the value of adjuvant treatment with chemotherapy and/or prophylactic lung irradiation. Cancer 61:1024-1031, 1988.
6. De Baere T, Vanel D, Shapeero LG, et al: Osteosarcoma after chemotherapy: Evaluation with contrast material-enhanced subtraction MR imaging. Radiology 185:587-592, 1992.
7. Du Bois D, Du Bois EF: A formula to estimate the approximate surface area if height and weight be known. Nutrition 5:303-311, 1989.
8. Eilber F, Giuliano A, Eckardt J, et al: Adjuvant chemotherapy for osteosarcoma: A randomized prospective trial. J Clin Oncol 5:21-26, 1987.
9. Enneking WF, Spanier SS, Goodman M: Current concepts review: Surgical staging of musculoskeletal sarcoma. J Bone Joint Surg 62A:1027-1030, 1980.
10. Erlemann R, Sciuk J, Bosse A, et al: Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: Assessment with dynamic and static MR imaging and skeletal scintigraphy. Radiology 175:791-796, 1990.
11. Glasser DB, Lane JM, Huvos AG, Marcove RC, Rosen G: Survival, prognosis, and therapeutic response in osteogenic sarcoma. Cancer 69:698-708, 1992.
12. Goorin AM, Abelson HT, Frei III E: Osteosarcoma: Fifteen years later. N Engl J Med 313:1637-1641, 1985.
13. Hanna J, Parham DM, Fairclough DL, et al: Assessment of osteosarcoma response to preoperative chemotherapy using dynamic FLASH gadolinium-DTPA-enhanced magnetic resonance mapping. Invest Radiol 27:367-373, 1992.
14. Heymsfield SB, Fulenwider T, Nordlinger B, et al: Accurate measurement of liver, kidney, and spleen volume and mass by computerized axial tomography. Ann Intern Med 90:185-187, 1979.
15. Holscher HC, Bloem JL, Nooy MA, et al: The value of MR imaging in monitoring the effect of chemotherapy on bone sarcoma. Am J Roentgenol 154:763-769, 1990.
16. Holscher HC, Bloem JL, Van der Woude H-J, et al: Can MRI predict the histopathologic response in patients with osteosarcoma after the first cycle of chemotherapy? Clin Radiol 50:384-390, 1995.
17. Hudson M, Jaffe R, Jaffe N, et al: Pediatric osteosarcoma: Therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol 8:1988-1997, 1990.
18. Huvos AG, Rosen G, Marcove RC: Primary osteogenic sarcoma: Pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 101:14-18, 1977.
19. Link MP, Goorin AM, Miser AW, et al: The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314:1600-1606, 1986.
20. Meyers PA, Heller G, Healey J, et al: Chemotherapy for nonmetastatic osteosarcoma. The Memorial Sloan-Kettering experience. J Clin Oncol 10:5-15, 1992.
21. Okasawara K, Une Y, Nakajima Y, Uchino J: The significance of measuring liver volume using computed tomographic images before and after hepatectomy. Jpn J Surg 25:43-48, 1995.
22. Onda M, Matsuda S, Higaki S, et al: ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 77:71-78, 1996.
23. Picci P, Bacci G, Campanacci M, et al: Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of variable and non-viable tumor. Cancer 56:1515-1521, 1985.
24. Pochanugool L, Subhadharaphandou T, Dhanachai M, et al: Prognostic factor among 130 patients with osteosarcoma. Clin Orthop 345:206-214, 1997.
25. Rosen G, Caparros B, Huvos AG, et al: Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221-1230, 1982.
26. Rosen G, Marcove RC, Caparros B, et al: Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery. Cancer 43:2163-2177, 1979.
27. Rosen G, Murphy ML, Huvos AG, Gutierrez M, Marcove RC: Chemotherapy, en bloc resection and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer 37:1-11, 1976.
28. Scranton P, DeCicco F, Totten T, Yunis EJ: Prognostic factors in osteosarcoma: A review of 20 years experience at the University of Pittsburgh Health Center Hospital. Cancer 36:2179-2191, 1975.
29. Sonderlund V, Larsson SA, Bauer HCF, et al: Use of 99mTc-MIBI scintigraphy in the evaluation of the response of osteosarcoma to chemotherapy. Eur J Nucl Med 24:511-515, 1997.
30. Spanier SS, Shuster JJ, Vander Griend RA: The effect of local extent of the tumor on prognosis in osteosarcoma. J Bone Joint Surg 72A:643-653, 1990.
31. Taylor WF, Ivins JC, Dahlin DC, Edmonson JH, Pritchard DJ: Trends and variability in survival from osteosarcoma. Mayo Clin Proc 53:695-700, 1978.
32. Taylor WF, Ivins JC, Pritchard DJ, et al: Trends and variability in survival among patients with osteosarcoma: A 7-year update. Mayo Clin Proc 60:91-104, 1985.
33. Uozaki H, Horiuchi H, Ishida T, et al: Overexpression of resistance-related protein (metallothioneins, glutathion-S-transferase pi, heat shock protein 27 and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis. Cancer 79:2336-2344, 1997.
34. Van der Woude HJ, Bloem JL, Hogendoorn PCW: Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing's sarcoma: Review of current imaging modalities. Skeletal Radiol 27:57-71, 1998.
35. Van der Woude HJ, Bloem JL, van Oostayen JA, et al: Treatment of high-grade bone sarcomas with neoadjuvant chemotherapy: The utility of sequential color Doppler sonography in predicting histopathologic response. Am J Roentgenol 165:125-133, 1995.
36. Welling RM, Davies AM, Pynsent PB, Carter SR, Grimer RJ: The value of computed tomographic measurements in osteosarcoma as a predictor of response to adjuvant chemotherapy. Clin Radiol 49:19-23, 1994.
37. Willen H: Tumor necrosis and prognosis in osteosarcoma. Acta Orthop Scand 273(Suppl): 126-129, 1997.
38. Yamamura H, Yoshikawa, H, Tatsuta M, Akedo H, Takahashi K: Expression of the smooth muscle calponin gene in human osteosarcoma and its possible association with prognosis. Int J Cancer 79:245-250, 1998.